Tags : AveXis

Weekly Snapshot

PharmaShots Weekly Snapshot (May 18-22, 2020)

1. BMS Reports EMA’s Validation of MAA for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486 Published: May 22, 2020 | Tags: bb2121, BMS ,CC-486, EMA, ide-cel Idecabtagene, Vicleucel MAA 2. Gilead Plans to Submit MAA to CDSCO for its Remdesivir to Treat COVID-19 in India Published: May 21, 2020 | Tags: Gilead, Plans, Submit, MAA, CDSCO, Remdesivir, COVID-19, […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (October 07-11, 2019)

OraSure Technologies’ Rapid Diagnostic OraQuick Ebola Rapid Antigen Test Receives the US FDA Marketing Approval for Detection of Ebola Virus Antigens Published: Oct 10, 2019 | Tags: Diagnostic, Oraquick Ebola Rapid Antigen Test, Orasure Technologies, Rapid, Receives, The US FDA, Marketing, Approval, Detection, Ebola Virus Antigens 2. Alnylam Reports Submission of MAA to Brazilian Health Regulatory […]Read More

Top 20

Top 20 Biopharma Acquisitions of 2018 Based on the Total

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 […]Read More


AveXis to Purchase Biologics Manufacturing Facility in Colorado

Shots: AveXis, a Novartis company purchases gene therapy manufacturing unit in Longmont, an addition to Durham facility of $115M investment, offering positions for 150 employees previously working at the site and further expansion of new jobs in H2’19 The focus of purchase is to expand the production unit leading to the preparation of Zolgensma’s (onasemnogene […]Read More


Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates

Shots: Novartis acquires AveXis, in all stock transaction with its AVXS-101 candidate for replacing the defective SMN1 gene. AveXis to receive $218/share making total deal value $8.7B The focus of the agreement is to utilize AveXis’ AAV9 gene therapy platform to develop therapies for multiple therapeutic areas AVXS-101 is a gene replacement therapy candidate targeted […]Read More